ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH® Personal Diabetes Managers ...

The FDA posted a notice saying the recall of Insulet's Omnipod DASH Insulin Management System Personal Diabetes Manager is a Class I, the most serious recall indicating the devices could cause serious ...

Insulet has begun a voluntary recall of the remote-control devices used with its Omnipod Dash insulin pumps after discovering that the devices’ batteries may be at risk of swelling, leaking or ...

Insulet has issued an alert for a data breach that may have compromised the health data of thousands of users of its Omnipod Dash insulin pumps. The devicemaker notified affected users and filed a ...

Insulet’s modeled fair value has been trimmed slightly from US$340.26 to US$326.35, indicating a more conservative price target in the updated analysis. This adjustment aligns with the mixed analyst ...

Medical Device Correction impacts only specific lots of Omnipod® 5 Pods Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods ...

Insulet PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, its heavy reliance on the Omnipod System and a ...

The U.S. Food and Drug Administration (FDA) has classified a recall of Insulet Corporation's PODD Omnipod 5 Pods as its most ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...